Genocea Biosciences, Inc. (GNCA) stock soared 55.07% in the pre-market trading session at the price of $0.62 after reporting positive data from TiTAN Phase 1/2a clinical trial.
TiTAN Clinical Trial Positive Data
On 8th April 2022, GNCA presented its preclinical and clinical results at AACR 2022 annual conference held virtually in New Orleans. The presentations comprised of favorable initial results from the TiTAN trial evaluating GEN-011, a product candidate for NPT therapy. The topline results also ensure successful manufacturing of GEN-011 through GNCA’s PLANET production technique.
The TiTAN Phase 1/2a trial examines the T-cell proliferation, clinical activity, safety, and tolerability of GEN-011 in adult patients having refractory solid-type tumors. The outcomes presented at AACR reveal the anti-tumor nature of the drug despite the highly pretreated tumors and low-intensity regimens. All patients experienced PD (progressive disease) at their 113th-day scan, while three out of the five underwent sharp biologic shifts after drug intake.
GNCA has had a 100 percent success rate in producing GEN-011 using its PLANET technique till now. The clinical activity of the drug had based upon reductions in expected ctDNA after therapy in the patients. The drug showed no evidence of auto-immune toxicity or self-reactivity, and none of the patients have undergone dose-related toxicities. Altogether, the range of Grade 3 and Grade 2 TEAEs align with anticipated toxicity from cell therapy regions.
Current Market Scenario
GNCA is employing its ATLAS bioassay approach to target neoantigens in GEN-011 to deliver promising results in patients. The clinical activity of this drug demonstrates that the neoantigen targeted cells are identifying and confronting the tumor, which is a very optimistic sign of its potential for better activity in highly intense regimens. Further, the company continued to make advancements in its PLANET manufacturing technique, which will produce more satisfactory clinical results in the coming future. The stock has expected to publish additional details by Q4 of 2022.